

Reward Deficiency Syndrome Studies of KB220 Variants and Molecular Neurobiology

Obesity

1. **Blum K**, Thanos PK, Gold MS. Dopamine and glucose, obesity, and reward deficiency syndrome. *Front Psychol.* 2014 Sep 17;5:919.
2. **Blum K**, Liu Y, Shriner R, Gold MS. Reward circuitry dopaminergic activation regulates food and drug craving behavior. *Curr Pharm Des.* 2011;17(12):1158-67.
3. Downs BW, Chen AL, Chen TJ, Waite RL, Braverman ER, Kerner M, Braverman D, Rhoades P, Prihoda TJ, Palomo T, Oscar-Berman M, Reinking J, Blum SH, DiNubile NA, Liu HH, **Blum K**. Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map? *Med Hypotheses.* 2009 Sep;73(3):427-34.
4. **Blum K**, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mangucci JF, Braverman ER, Arcuri V, Varshavskiy M, Deutsch R, Martinez-Pons M. Reward deficiency syndrome in obesity: a preliminary cross-sectional trial with a Genotrim variant. *Adv Ther.* 2006 Nov-Dec;23(6):1040-51.
5. **Blum K**, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mangucci JF, Braverman ER, Arcuri V, Deutsch R, Pons MM. Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). *Med Hypotheses.* 2007;68(4):844-52.
6. Yarnell S, Oscar-Berman M, Avena N, **Blum K**, Gold M. Pharmacotherapies for Overeating and Obesity. *J Genet Syndr Gene Ther.* 2013 Apr 1;4(3):131.
7. **Blum K**, Bailey J, Gonzalez AM, Oscar-Berman M, Liu Y, Giordano J, Braverman E, Gold M. Neuro-Genetics of Reward Deficiency Syndrome (RDS) as the Root Cause of "Addiction Transfer": A New Phenomenon Common after Bariatric Surgery. *J Genet Syndr Gene Ther.* 2011 Dec 23;2012(1). pii: S2-001.
8. Chen AL, **Blum K**, Chen TJ, Giordano J, Downs BW, Han D, Barh D, Braverman ER. Correlation of the Taq1 dopamine D2 receptor gene and percent body fat in obese and screened control subjects: a preliminary report. *Food Funct.* 2012 Jan;3(1):40-8
9. **Blum K**, Chen AL, Chen TJ, Rhoades P, Prihoda TJ, Downs BW, Waite RL, Williams L, Braverman ER, Braverman D, Arcuri V, Kerner M, Blum SH, Palomo T. LG839: anti-**obesity** effects and polymorphic gene correlates of reward deficiency syndrome. *Adv Ther.* 2008 Sep;25(9):894-913. \
10. **Blum K**, Braverman ER, Wood RC, Gill J, Li C, Chen TJ, Taub M, Montgomery AR, Sheridan PJ, Cull JG. Increased prevalence of the Taq 1 A1 allele of the dopamine receptor gene (DRD2) in **obesity** with comorbid substance use disorder: a preliminary report. *Pharmacogenetics.* 1996 Aug;6(4):297-305.
11. Blum K, Stice E, Liu Y, Giordano J, Morse S, et al. (2011) "Dopamine Resistance" in brain reward circuitry as a function of DRD2 gene receptor polymorphisms in RDS: Synaptamine complex variant (KB220) induced "Dopamine Sensitivity" and enhancement of happiness. XIX World Congress of Psychiatric Genetics, September 10-14th, Washington DC.
12. Blum K, Chen TJH, Chen ALC, Rhodes P, Prihoda TJ, et al. (2008) Dopamine D2 Receptor Taq A1 allele predicts treatment compliance of LG839 in a subset analysis of pilot study in the Netherlands. *Gene Ther Mol Biol* 12: 129-140.
13. Chen TJH , Blum K, Kaats G, Braverman ER, Eisenberg A, et al. (2007) Chromium Picolinate (Crp) a putative Anti-Obesity Nutrient Induces Changes In Body Composition As Function Of The Taq1 Dopamine D2 Receptor polymorphisms in a randomized double-blind placebo controlled study. *Gene Therapy and Molecular Biology* 11: 161-170.
14. Blum K, Trachtenberg MC, Cook DW (1990) Neuronutrient effects on weight loss in carbohydrate bingers; an open clinical trial. *Curr Ther Res* 48: 217-233.
15. Blum K, Cull JG, Chen TJH, Swan SG, Holder JM, et al. (1997) Clinical evidence for effectiveness of Phencal™ in maintaining weight loss in an open-label, controlled, 2-year study. *Current Therapeutic Research* 58: 745-763.
16. 1st Conference on Reward Deficiency Syndrome: Genetic Antecedents and Clinical Pathways. San Francisco, California, USA. November 12-13, 2000. Abstracts. Amino-acid precursor and enkephalinase inhibition therapy: evidence for effectiveness in treatment of "Reward Deficiency Syndrome (RDS) with particular emphasis on eating disorders. *Julia Ross. Mol Psychiatry.* Feb; 6(1 Suppl 1):S1-8, 2001.
17. Blum K, Chen TJH, Williams L, Chen ALC, Downs WB, et al. (2008) A short term pilot open label study to evaluate efficacy and safety of LG839, a customized DNA directed nutraceutical in obesity: Exploring Nutrigenomics. *Gene Ther Mol Biol* 12: 371-382.
18. Blum K, Chen AL, Chen TJ, Rhoades P, Prihoda TJ, et al. (2008) LG839: anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome. *Adv Ther* 25: 894-913.
19. Braverman ER, Braverman D, Arcuri V, Kerner M, Downs BW, Blum K (2010) Sustainable Weight Loss and Muscle Gain Utilizing the Rainbow Diet™: Targeting Noradrenergic and dopaminergic Mechanistic Sites, Hormonal Deficiency Repletion Therapy and Exercise: A case report. *The American Journal of Bariatric Medicine* 25: 18-28.

Drug Addiction

1. Blum K, Calhoun W, Merritt J, Wallace JE (1973) L-DOPA: effect on ethanol narcosis and brain biogenic amines in mice. *Nature* 242: 407-409.

2. Blum K, Wallace JE, Calhoun W, Tabor RG, Eubanks JD (1974) Ethanol narcosis in mice: serotonergic involvement. *Experientia* 30:1053–1054.
3. Blum K, Allison D, Trachtenberg MC, Williams RW, Loeblich LA (1988) Reduction of both drug hunger and withdrawal against advice rate of cocaine abusers in a 30 day inpatient treatment program by the neuronutrient Tropamine. *Current Therapeutic Research* 43: 1204–1214.
4. Blum K, Briggs AH, Trachtenberg MC, Delallo L, Wallace JE, (1987) Enkephalinase inhibition: regulation of ethanol intake in genetically predisposed mice. *Alcohol* 4:449–456.
5. Miller DK, Bowirrat A, Manka M, Miller M, Stokes S, et al. (2010) Acute intravenous synaptamine complex variant KB220™ “normalizes” neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports. *Postgrad Med* 122: 188–213.
6. Blum K, Chen TJ, Morse S, Giordano J, Chen AL, et al. (2010) Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D2 agonist therapy: part 2. *Postgrad Med* 122:214–226.
7. Blum K, Trachtenberg MC, Elliott CE, Dingler ML, Sexton RL (1988) Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double-blind placebo-controlled study of the nutritional adjunct SAAVE. *Alcohol* 5: 481–493.
8. Blum K, Trachtenberg MC, Ramsay JC (1988) Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: a pilot study. *The International Journal of the Addictions* 23: 991–998.
9. Brown RJ, Blum K, Trachtenberg MC (1990) Neurodynamics of relapse prevention: a neuronutrient approach to outpatient DUI offenders *Journal of Psychoactive Drugs* 22:173–187.
10. Blum K, Chen TJH, Downs BW, Meshkin B, Blum SH, et al. (2007) Synaptamine (SG8839), TM An Amino-Acid Enkephalinase Inhibition Nutraceutical Improves Recovery of Alcoholics, A Subtype of Reward Deficiency Syndrome (RDS). *Trends in Applied Sciences Research* 2 (3): 132–138.
11. Chen TJ, Blum K, Waite RL, Meshkin B, Schoolfield J, et al. (2007) Gene Narcotic Attenuation Program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome. *Advances in Therapy* 24:402–414.
12. Chen D, Liu Y, He W, Wang H, Wang Z (2012) Neurotransmitter-precursor-supplement Intervention for Detoxified Heroin Addicts. *Med Sci* 32: 422–427.
13. Chen TJ, Blum K, Payte JT, Schoolfield J, Hopper D, et al. (2004) Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. *Medical Hypotheses* 63: 538–548.
14. Cold, Julie A (1996) NeuRecover-SATM in the Treatment of Cocaine Withdrawal and Craving: A Pilot Study. *Clinical Drug Investigation* 12: 1–7.
15. **Blum K**, Liu Y, Wang W, Wang Y, Zhang Y, Oscar-Berman M, Smolen A, Febo M, Han D, Simpatico T, Cronjé FJ, Demetrovics Z, Gold MS. rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped **heroin** addicts. *Postgrad Med*. 2015 Mar;127(2):232-41.
16. Hill E, Han D, Dumouchel P, Dehak N, Quatieri T, Moehs C, Oscar-Berman M, Giordano J, Simpatico T, Barh D, **Blum K**. Long term Suboxone™ emotional reactivity as measured by automatic detection in speech. *PLoS One*. 2013 Jul 9;8(7):e69043. doi: 10.1371/journal.pone.0069043.
17. Chen TJ, **Blum K**, Chen AL, Bowirrat A, Downs WB, Madigan MA, Waite RL, Bailey JA, Kerner M, Yeldandi S, Majmundar N, Giordano J, Morse S, Miller D, Fornari F, Braverman ER. Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map. *J Psychoactive Drugs*. 2011 Apr-Jun;43(2):108-27.
18. Miller DK, Bowirrat A, Manka M, Miller M, Stokes S, Manka D, Allen C, Gant C, Downs BW, Smolen A, Stevens E, Yeldandi S, **Blum K**. Acute intravenous synaptamine complex variant KB220™ “normalizes” neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports. *Postgrad Med*. 2010 Nov;122(6):188-213.
19. Miller M, Chen AL, Stokes SD, Silverman S, Bowirrat A, Manka M, Manka D, Miller DK, Perrine K, Chen TJ, Bailey JA, Downs W, Waite RL, Madigan MA, Braverman ER, Damle U, Kerner M, Giordano J, Morse S, Oscar-Berman M, Barh D, **Blum K**. Early intervention of intravenous KB220IV--neuroadaptagen amino-acid therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: a pilot study. *J Psychoactive Drugs*. 2012 Nov-Dec;44(5):398-409
20. Blum K, Gold MS. Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis. *Med Hypotheses*. 2011 Apr;76(4):576-84.
21. Geller I, Hartmann R, Blum K. Effects of nicotine, nicotine monomethiodide, lobeline, chlordiazepoxide, meprobamate and caffeine on a discrimination task in laboratory rats. *Psychopharmacologia*. 1971;20(4):355-65.
22. Blum K, Oscar-Berman M, Femino J, Waite RL, Benya L, Giordano J, Borsten J, Downs WB, Braverman ER, Loehmann R, Dushaj K, Han D, Simpatico T, Hauser M, Barh D, McLaughlin T. Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note. *J Addict Res Ther*. 2013 Apr 23;4(2). doi: 10.4172/2155-6105.1000146.
23. Blum K, Chen TJ, Morse S, Giordano J, Chen AL, Thompson J, Allen C, Smolen A, Lubar J, Stice E, Downs BW, Waite RL, Madigan MA, Kerner M, Fornari F, Braverman ER. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D2 agonist therapy: part 2. *Postgrad Med*. 2010 Nov;122(6):214-26.
24. Blum K, Briggs AH, DeLallo L. Clonidine enhancement of ethanol withdrawal in mice. *Subst Alcohol Actions Misuse*. 1983;4(1):59-63.
25. Blum K, Futterman S, Wallace JE, Schwertner HA. Naloxone-induced inhibition of ethanol dependence in mice. *Nature*. 1977 Jan 6;265(5589):49-51.

26. Blum K, Eubanks JD, Wallace JE, Schwertner HA. Suppression of ethanol withdrawal by dopamine. *Experientia*. 1976 Apr 15;32(4):493-5.
27. Blum K, Trachtenberg MC, Elliott CE, Dingler ML, Sexton RL, Samuels AI, Cataldie L. Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double-blind placebo-controlled study of the nutritional adjunct SAAVE. *Alcohol*. 1988 Nov-Dec;5(6):481-93.
28. Blum K, Trachtenberg MC, Ramsay JC. Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: a pilot study. *Int J Addict*. 1988 Sep;23(9):991-8.
29. Blum K, Trachtenberg MC. Neurogenetic deficits caused by alcoholism: restoration by SAAVE, a neuronutrient intervention adjunct. *J Psychoactive Drugs*. 1988 Jul-Sep;20(3):297-313.
30. Trachtenberg MC, Blum K. Improvement of cocaine-induced neuromodulator deficits by the neuronutrient Tropicamide. *J Psychoactive Drugs*. 1988 Jul-Sep;20(3):315-31.
31. Blum K, Briggs AH, Wallace JE, Hall CW, Trachtenberg MA. Regional brain [Met]-enkephalin in alcohol-preferring and non-alcohol-preferring inbred strains of mice. *Experientia*. 1987 Apr 15;43(4):408-10.
32. Blum K, Badgaiyan RD, Agan G, Fratantonio J, Simpatico T, Febo M, Haberstick BC, Smolen A, Gold MS. Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction. *J Reward Defic Syndr*. 2015;1(1):65-68.
33. Blum K, Thanos PK, Badgaiyan RD, Febo M, Oscar-Berman M, Fratantonio J, Demetrovics Z, Gold MS. Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land? *Expert Opin Biol Ther*. 2015 Jul;15(7):973-85.
34. Blum K, Febo M, Thanos PK, Baron D, Fratantonio J, Gold M. Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner? *Mol Neurobiol*. 2015 Dec;52(3):1862-9.
35. Blum K, Oscar-Berman M, Jacobs W, McLaughlin T, Gold MS. Buprenorphine Response as a Function of Neurogenetic Polymorphic Antecedents: Can Dopamine Genes Affect Clinical Outcomes in Reward Deficiency Syndrome (RDS)? *J Addict Res Ther*. 2014;5. pii: 1000185.
36. Blum K, Febo M, McLaughlin T, Cronjé FJ, Han D, Gold SM. Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)[™] as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric. *J Behav Addict*. 2014 Sep;3(3):149-56.

ADHD/PTSD

1. Modestino EJ, Blum K, Oscar-Berman M, Gold MS, Duane DD, Sultan SG, Auerbach SH. Reward Deficiency Syndrome: Attentional/Arousal Subtypes, Limitations of Current Diagnostic Nosology, and Future Research. *J Reward Defic Syndr*. 2015;1(1):6-9.
2. McLaughlin T, Blum K, Oscar-Berman M, Febo M, Demetrovics Z, Agan G, Fratantonio J, Gold MS. Using the Neuroadaptagen KB200z[™] to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis. *J Reward Defic Syndr*. 2015;1(1):24-35.
3. Gold MS, Blum K, Oscar-Berman M, Braverman ER. Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children? *Postgrad Med*. 2014 Jan;126(1):153-77.
4. Archer T, Oscar-Berman M, Blum K. Epigenetics in Developmental Disorder: ADHD and Endophenotypes. *J Genet Syndr Gene Ther*. 2011 Jun 30;2(104). pii: 1000104.
5. Braverman ER, Chen AL, Chen TJ, Schoolfield JD, Notaro A, Braverman D, Kerner M, Blum SH, Arcuri V, Varshavskiy M, Damle U, Downs BW, Waite RL, Oscar-Berman M, Giordano J, Blum K. Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia. *Neuropsychiatr Dis Treat*. 2010 Oct 15;6:681-90.
6. Blum K, Chen AL, Braverman ER, Comings DE, Chen TJ, Arcuri V, Blum SH, Downs BW, Waite RL, Notaro A, Lubar J, Williams L, Prihoda TJ, Palomo T, Oscar-Berman M. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. *Neuropsychiatr Dis Treat*. 2008 Oct;4(5):893-918.
7. Braverman ER, Chen TJ, Schoolfield J, Martinez-Pons M, Arcuri V, Varshavskiy M, Gordon CA, Mengucci J, Blum SH, Meshkin B, Downs BW, Blum K. Delayed P300 latency correlates with abnormal Test of Variables of Attention (TOVA) in adults and predicts early cognitive decline in a clinical setting. *Adv Ther*. 2006 Jul-Aug;23(4):582-600.
8. Comings DE, Chen TJ, Blum K, Mengucci JF, Blum SH, Meshkin B. Neurogenetic interactions and aberrant behavioral comorbidity of attention deficit hyperactivity disorder (ADHD): dispelling myths. *Theor Biol Med Model*. 2005 Dec 23;2:50.
9. Blum K, Braverman ER, Holder JM, Lubar JF, Monastera VJ, Miller D, Lubar JO, Chen TJ, Comings DE. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. *J Psychoactive Drugs*. 2000 Nov;32 Suppl:i-iv, 1-112.
10. Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. *Prog Brain Res*. 2000;126:325-41.
11. Blum K, Braverman ER, Wu S, Cull JG, Chen TJ, Gill J, Wood R, Eisenberg A, Sherman M, Davis KR, Matthews D, Fischer L, Schnautz N, Walsh W, Pontius AA, Zedar M, Kaats G, Comings DE. Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB). *Mol Psychiatry*. 1997 May;2(3):239-46.
12. DeFrance JF, Hymel C, Trachtenberg MC, Ginsberg LD, Schweitzer FC, Estes S, Chen TJ, Braverman ER, Cull JG, Blum K. Enhancement of attention processing by Kantroll in healthy humans: a pilot study. *Clin Electroencephalogr*. 1997 Apr;28(2):68-75.
13. Blum K, Wood RC, Braverman ER, Chen TJ, Sheridan PJ. The D2 dopamine receptor gene as a predictor of compulsive disease: Bayes' theorem. *Funct Neurol*. 1995 Jan-Feb;10(1):37-44.
14. McLaughlin T, Blum K, Oscar-Berman M, Febo M, Agan G, Fratantonio JL, Simpatico T, Gold MS. Putative dopamine agonist (KB220Z) attenuates lucid nightmares in PTSD patients: role of enhanced brain reward functional connectivity and homeostasis redeeming joy. *J Behav Addict*. 2015 Jun;4(2):106-15. doi: 10.1556/2006.4.2015.008.

15. Blum K, Giordano J, Oscar-Berman M, Bowirrat A, Simpatico T, Barh D. Diagnosis and Healing In Veterans Suspected of Suffering from Post-Traumatic Stress Disorder (PTSD) Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic Activation. *J Genet Syndr Gene Ther.* 2012 May 31;3(3):1000116.
16. Bowirrat A, Chen TJ, Blum K, Madigan M, Bailey JA, Chuan Chen AL, Downs BW, Braverman ER, Radi S, Waite RL, Kerner M, Giordano J, Morse S, Oscar-Berman M, Gold M. Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability. *Curr Neuropharmacol.* 2010 Dec;8(4):335-58. doi: 10.2174/157015910793358123.
17. Blum K, Febo M, Smith DE, Roy AK 3rd, Demetrovics Z, Cronjé FJ, Femino J, Agan G, Fratantonio JL, Pandey SC, Badgaiyan RD, Gold MS. Neurogenetic and epigenetic correlates of adolescent predisposition to and risk for addictive behaviors as a function of prefrontal cortex dysregulation. *J Child Adolesc Psychopharmacol.* 2015 May;25(4):286-92.
18. Archer T, Oscar-Berman M, Blum K, Gold M. Neurogenetics and Epigenetics in Impulsive Behaviour: Impact on Reward Circuitry. *J Genet Syndr Gene Ther.* 2012 May 30;3(3):1000115
19. Blum K, Chen AL, Oscar-Berman M, Chen TJ, Lubar J, White N, Lubar J, Bowirrat A, Braverman E, Schoolfield J, Waite RL, Downs BW, Madigan M, Comings DE, Davis C, Kerner MM, Knopf J, Palomo T, Giordano JJ, Morse SA, Fornari F, Barh D, Femino J, Bailey JA. Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors. *Int J Environ Res Public Health.* 2011 Dec;8(12):4425-59.
20. Blum K, Gardner E, Oscar-Berman M, Gold M. "Liking" and "wanting" linked to Reward Deficiency Syndrome (RDS): hypothesizing differential responsivity in brain reward circuitry. *Curr Pharm Des.* 2012;18(1):113-8.
21. Blum K, Chen ALC, Chen TJH, Bowirrat A, Waite RL, et al. (2009) Putative targeting of Dopamine D2 receptor function in Reward Deficiency Syndrome (RDS) by Synaptamine Complex™ Variant (KB220): Clinical trial showing anti-anxiety effects. *Gene Ther Mol Biol* 13:214–230.
22. Braverman ER, Blum K. P300 (latency) event-related potential: an accurate predictor of memory impairment. *Clin Electroencephalogr.* 2003 Jul;34(3):124-39.
23. Steinberg B, Blum , McLaughlin T, Lubar J, Febo M, Braverman, ER ,Badgaiyan RD. Pro-Dopamine Regulator -KB220Z™ induced activation of anterior cingulate and dorsolateral prefrontal cortices as displayed by low-resolution electromagnetic tomographic (LORETA) in an ADHD Case Study. *Journal of Cases in Neurology* (to be submitted)

Sexual Addiction

1. Blum K, Badgaiyan RD, Gold MS. Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics. *Cureus.* 2015 Oct 12;7(10):e348. doi: 10.7759/cureus.348.
2. Blum K, Thompson B, Oscar-Berman M, Giordano J, Braverman E, Femino J, Barh D, Downs W, Smpatico T, Schoenthaler S. Genospirituality: Our Beliefs, Our Genomes, and Addictions. *J Addict Res Ther.* 2013 Oct 10;5(4). pii: 162.
3. Blum K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, Oscar-Berman M, Gold M. Sex, drugs, and rock 'n' roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms. *J Psychoactive Drugs.* 2012 Jan-Mar;44(1):38-55
4. Braverman ER, Chen TJ, Chen AL, Kerner MM, Tung H, Waite RL, Schoolfield J, Blum K. Preliminary investigation of plasma levels of sex hormones and human growth factor(s), and P300 latency as correlates to cognitive decline as a function of gender. *BMC Res Notes.* 2009 Jul 7;2:126. doi: 10.1186/1756-0500-2-126.
5. Blum K, Chen AL, Chen TJ, Braverman ER, Reinking J, Blum SH, Cassel K, Downs BW, Waite RL, Williams L, Prihoda TJ, Kerner MM, Palomo T, Comings DE, Tung H, Rhoades P, Oscar-Berman M. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. *Theor Biol Med Model.* 2008 Nov 12;5:24.
6. Mclaughlin T, Oscar-Berman M, Simpatico T and Blum K . Hypothesizing repetitive paraphilia behavior of a medication refractive Tourettes ‘ Syndrome patient having rapid clinical attenuation with KB220z NAAT. *JBA* 2(2) 117-124 ,2013.